Laboratoire Dazont has been acquired by SBM Company
The shareholders of Laboratoire Dazont have sold the company to SBM Company.
Created in 2008, Laboratoire Dazont is a France-based company specialized in the design, manufacture and distribution of natural veterinary solutions for pharmacies and parapharmacies. The company offers a complete range of approximately 50 references of natural products, including aromatherapy, petcare, and products and food supplements for dogs and cats under the Vetoform and Vetonut brands. Laboratoire Dazont offers its solutions to 750 pharmacies and parapharmacies in France, including key accounts such as E. Leclerc and Santédiscount.
Created in 1994, SBM Company is a family-owned French group with presence in more than 31 countries throughout Europe and North America. SBM designs, homologates, produces and markets products for the care and protection of crops, gardens and homes. In 2021, the group generated approximately US$360 million in sales, 60% internationally.
Oaklins’ team in France acted as M&A advisor to Laboratoire Dazont in the disposal of the company to SBM Company.
Contacter l'équipe de la transaction
Transactions connexes
Bayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
En apprendre plusVivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
En apprendre plusCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
En apprendre plus